Foster City, CA, December 19, 2007 – Entelos, Inc. (LSE: ENTL), a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (“J&JPRD”), under which Entelos will use its “virtual patients” approach as a platform to discover and evaluate potential new therapies for treating type-2 diabetes. Financial terms were not disclosed.

"Finding the optimal therapies and treatment regimens for specific patient types is a key strength of our in silico disease platforms," stated James Karis, president and CEO of Entelos. "The deal reinforces Entelos' stated strategy to enable proprietary drug development, particularly in chronic disease areas where multiple drugs, treatment choices, and large differences between patients make it difficult for health-care providers to select the best treatments. Type 2 diabetes is a classic example, where several standard therapies are available to treat most patients in the earliest phases of their disease, but where diet, exercise, multiple new drugs, or even surgery could be considered to gain better control of high-blood sugar levels over the long term. We look forward to our continued work in diabetes, an area of great medical need."

For further information please contact:

Entelos, Inc.
James Karis, President and CEO
Jill Fujisaki, VP, Investor Relations
Tel: +1 650 572 5400

Buchanan Communications
Lisa Baderoon
Mary-Jane Johnson
Tel +44 (0) 20 7466 5000

Notes for Editors

About Entelos
Entelos, Inc. (www.entelos.com) is a US-based life sciences company applying next-generation predictive technologies to revolutionize the way medicines are discovered, developed, and utilized. The Company leverages its proprietary in silico disease models, “virtual patients”, and toxicology reference systems to develop safer and more effective drugs and support pharmaceutical R&D and commercialization. In addition to internal drug programs in rheumatoid arthritis and women's health, Entelos provides customized technology and research services to global pharmaceutical and health-care companies in cardiovascular diseases, asthma, obesity, diabetes, hematopoeisis (anemia), cholesterol metabolism, and skin sensitization. The company is also developing a model in oncology and is collaborating with the FDA to build a model of drug-induced liver injury. Entelos also offers cost-effective drug development capabilities through its strategic alliance with India-based Jubilant Biosys.

Entelos is a registered trademark of Entelos, Inc. PhysioLab is a trademark and service mark of Entelos, Inc.
All other trademarks are the property of their registered owners